Does Trump's MFN Policy Put Pharma ETFs in the Crosshairs?

Pharma giants Eli Lily ((LLY) and Novo Nordisk ((NVO) have signed deals with U.S. President Donald Trump to slash the prices of some of their obesity drugs, including upcoming pills, as per a White House announcement made late last week. This comes as part of the Trump administration’s Most-Favored-Nation (“MFN”) drug pricing policy that aims at forcing U.S. drug prices to match the lowest prices available in other advanced countries. Such price cuts pose a direct financial challenge to the pharma industry, ...